The U.S. Food and Drug Administration (FDA) has agreed that a 42-year-old man with prodromal, or early stage, multiple system atrophy (MSA) , a form of atypical parkinsonism, be treated with ENT-01, Enterin’s investigational therapy for reducing the accumulation of toxic alpha-synuclein in gut nerve cells. Treatment will…
Enrollment is now open across all 38 clinical sites in the Phase 2b trial testing pirepemat (previously known as IRL752), IRLAB Therapeutics’ investigational therapy intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. The Phase 2b trial (NCT05258071) is recruiting Parkinson’s…
Alterity Therapeutics’ new Phase 2 clinical trial testing ATH434 in patients with multiple system atrophy (MSA), a form of atypical parkinsonism, has enrolled its first patient, the company announced. The open-label, biomarker ATH434-202 study (NCT05864365) is enrolling 15 adults, ages 30-75 years, with advanced MSA and…
The first patient has been dosed in a Phase 2 trial testing BIA 28-6156, Bial’s investigational therapy for Parkinson’s disease patients with mutations in the glucocerebrosidase 1 (GBA1) gene. The ACTIVATE (NCT05819359) study is currently screening Parkinson’s patients, ages 35 to 80 years, across multiple sites in…
NurrOn Pharmaceuticals has partnered with South Korean HanAll Biopharma and Daewoong Pharmaceutical to continue developing its candidate therapy for Parkinson’s disease and other neurodegenerative disorders. A Phase 1 clinical trial of its lead oral investigational therapy ATH-399A is expected to start this year. Before testing it…
The Michael J. Fox Foundation (MJFF) is partnering with H1 to enhance the connections between physicians, researchers and patients with Parkinson’s disease. MJFF will use H1’s Trial Landscape platform to identify and communicate with lead researchers and physicians treating Parkinson’s patients, including those in populations typically unrepresented…
The natural brain-produced steroid pregnenolone showed benefits in a rat model of Parkinson’s disease, where it was found to slow the development of levodopa-induced dyskinesia, or uncontrollable involuntary movements. Importantly, the treatment did not affect levodopa-induced motor improvements in the model. “Our data suggest that restoring…
The Van Andel Institute has awarded scientist Virginia M.Y. Lee the 2023 Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research. in recognition of her pioneering work in Parkinson’s disease. “It is an absolute honor to present Dr. Lee with the Jay Van Andel Award for…
NeuroRPM, an artificial intelligence (AI)-powered app designed to continuously monitor hallmark symptoms of Parkinson’s disease has been cleared for use by the U.S. Food and Drug Administration (FDA). “The clearance of NeuroRPM is a major milestone in the fight against Parkinson’s disease,” Alexander Ksendzovsky, MD, PhD, cofounder and chief…
Note: This story was updated March 24, 2023, to correct the name of CND Life Sciences. CND Life Sciences has signed a licensing and collaboration agreement with Beth Israel Deaconess Medical Center (BIDMC) in Boston to develop minimally invasive, diagnostic tests for Parkinson’s and other neurodegenerative diseases. The…
Get regular updates to your inbox.